Institute of Haematology "L. e A. Seràgnoli", University of Bologna, Via Massarenti, 9 -40138, Bologna, Italy.
BMC Cancer. 2018 Jun 8;18(1):645. doi: 10.1186/s12885-018-4561-9.
No standard of care is established for plasmablastic lymphoma (PBL) and prognosis remains extremely poor, given that patients relapse early after chemotherapy and display resistance to commonly applied cytostatic drugs.
We report a case of nodal, HIV-unrelated PBL in a patient who achieved and maintained a very long lasting complete remission after an intensive therapy consisting consisting of thalidomide plus dexamethasone followed by a consolidation with double autologous stem cell transplantation. Our approach was based on the full application of a standard multiple myeloma treatment and, to the best of our knowledge, it represents the only reported experience so far. This treatment was overall well tolerated.
Multiple myeloma-like treatment may represent a possible alternative to intensive lymphoma-directed therapies.
尚无针对浆母细胞淋巴瘤(PBL)的标准治疗方法,由于患者在化疗后早期复发且对常用细胞毒药物产生耐药,因此预后极差。
我们报告了一例与 HIV 无关的淋巴结 PBL 病例,患者在接受沙利度胺联合地塞米松强化治疗后达到并维持了非常持久的完全缓解,随后进行了双次自体干细胞移植巩固治疗。我们的方法基于充分应用标准的多发性骨髓瘤治疗方案,据我们所知,这是迄今为止唯一报道的经验。这种治疗总体上耐受性良好。
类似于多发性骨髓瘤的治疗方法可能是一种替代强化淋巴瘤定向治疗的选择。